| Verifiedrevid: | 415855405 |
| Iupac Name: | N-[2-(1H-indol-3-yl)ethyl]-N-methylpropan-2-amine |
| Imagel: | MIPT.svg |
| Widthl: | 140 |
| Imager: | Methylisopropyltryptamine.png |
| Widthr: | 140 |
| Legal Au: | Unscheduled |
| Legal Ca: | Unscheduled |
| Legal De: | NpSG |
| Legal Uk: | Class A |
| Legal Us: | Unscheduled |
| Cas Number: | 96096-52-5 |
| Pubchem: | 29935323 |
| Chemspiderid: | 21106353 |
| Chembl: | 353728 |
| Unii: | JO3SCR302A |
| C: | 14 |
| H: | 20 |
| N: | 2 |
| Smiles: | CC(C)N(C)CCc1c[nH]c2ccccc12 |
| Stdinchi: | 1S/C14H20N2/c1-11(2)16(3)9-8-12-10-15-14-7-5-4-6-13(12)14/h4-7,10-11,15H,8-9H2,1-3H3 |
| Stdinchikey: | KTQJVAJLJZIKKD-UHFFFAOYSA-N |
N-methyl-N-isopropyltryptamine (MiPT) is a psychedelic tryptamine, closely related to DMT, DiPT and miprocin. It was first synthesized by David Repke in 1984[1] and was subsequently evaluated and described in Alexander Shulgin's 1997 book TiHKAL.
MiPT is the N-isopropyl analog of DMT and the N-methyl analog of DiPT.
MiPT base, unlike many other tryptamines in their freebase form, does not decompose rapidly in the presence of light or oxygen.
In August 2019, Chadeayne et al. solved the crystal structure of fumarate salt of MiPT.[2]
Moderate effects have been reported at 10-25 mg ingested orally, with effects lasting 4–8 hours. One of the test subjects in TiHKAL reported moderate effects at 20 mg ingested intranasally.
In TiHKAL, the subjective experience is reported to be biased towards mental (psychedelic/entheogenic) effects, with mild perceptual (sensory/hallucinogenic) alterations relative to other tryptamines.[3] Subjects reported enhancement of the visual field (brightened and modulated color perception) but a lack of visual distortion typical of tryptamines such as psilocin. Enhancement of auditory perception was also noted. Documented physical effects include stimulation, dry mouth, and muscle tension.
In the United States, MiPT is unscheduled but purchase, sale, or possession for human consumption could be prosecuted under the Federal Analogue Act.[4] MiPT is specifically mentioned in the DEA Orange Book.[5]
Sweden's public health agency suggested classifying MiPT as a hazardous substance, on May 15, 2019.[6]